Acquisition

Synexus Clinical Research PLC
24 October 2006


SNX.L

                         Synexus Clinical Research PLC

             Acquisition of Clinical Research Centers SA (PTY) Ltd

Synexus Clinical Research PLC ('Synexus' or 'Company'), the clinical trials
services group, today announces that it has entered into a conditional agreement
to acquire the entire issued share capital of Clinical Research Centers SA (PTY)
Ltd ('CRC') for an initial consideration of £0.81m plus a maximum deferred
consideration of £0.98m. The acquisition is conditional upon approval being
received in respect of certain terms of the transaction from the South African
Reserve Bank.

This acquisition, the Company's third since joining AIM in November 2005,
follows its stated strategy to build a multi-country operation, replicating its
UK capability of recruiting large numbers of patients into later stage clinical
trials for the pharmaceutical industry.

Information on CRC

CRC is a Site Management Organisation based in South Africa providing clinical
trial services, particularly the recruitment and subsequent management of
patients onto later stage clinical trials for the pharmaceutical industry.

Benefits of the acquisition

• CRC represents a further opportunity for the Company to exploit the
growing clinical trials and patient recruitment markets in emerging economies.

• The acquisition of CRC, a well-established business operating in the
same area of activity as Synexus, complements the organic growth of the Company.

• The acquisition of CRC is expected to be earnings accretive for
Synexus for the year to 31 March 2007.

• The acquisition both broadens the therapeutic offering of Synexus and
provides access to a significant pool of previously untreated patients for
clinical trials

Details of the acquisition

The maximum consideration of £1.80m is satisfied as follows:

• £0.81m payable on completion (of which £0.25m is payable by way of the
issue of 266,109 new ordinary shares in Synexus and the remainder in cash).

• £0.25m deferred consideration payable in cash after completion of the
Synexus year end audit.

• Up to a further £0.74m payable in cash and shares, dependent on the
level of profit after tax of CRC for the year ending 31 March 2008.

In addition to its core later stage clinical trials business, CRC owns a 49%
interest in AddClin Research (Pty) Ltd ("AddClin"), a joint venture with Adcock
Ingram, the large South African multinational pharmaceutical business. Addclin
carries out bioequivalence and pharmacokinetic studies for South African and
international generics companies.

Commenting on the acquisition, Michael Fort, Chief Executive of Synexus said:

"We are delighted with the acquisition of CRC which not only extends our
therapeutic range but also gives us a footprint in the Southern Hemisphere where
we will be able to conduct contra-seasonal studies to those in the Northern
Hemisphere into conditions such as hay fever and asthma, thereby extending our
offering in these areas.

"The interest in the joint venture in Phase I studies with Adcock Ingram is also
exciting as this is not only a link with a large multinational healthcare
company but is also a low risk entry into the early stage market.

"We are especially pleased to welcome CRC's founder and managing director, Dr
Sanet Aspinall to the operations board of Synexus Clinical Research plc. Her
experience at the highest level within the medical community in South Africa
will be of considerable value to Synexus."

Note

An exchange rate of £1 : 13.95 Za Rand has been used in this announcement in
relation to the financial information on CRC. All payments of cash are to be
made in Za Rand.


Press enquiries

Synexus Clinical Research plc             Tel: [phone]
Michael Redmond, Chairman
Michael Fort, Chief Executive

Biddicks - Financial Public Relations     Tel: [phone]
Zoe Biddick

Brewin Dolphin Securities                 Tel: [phone]
Mark Brady/Sarah Kent




                      This information is provided by RNS
            The company news service from the London Stock Exchange